Crism Therapeutics annual ebitda
2023
2024
2025
Crism Therapeutics EBITDA Growth & History (CRTX)
Crism Therapeutics's calculated EBITDA was −£1.9M for fiscal 2025.
View full Crism Therapeutics company overviewCrism Therapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£1.9M | −£1.3M | — |
| 2024 | 2024-12-31 | −£566,000 | −£412,000 | — |
| 2023 | 2023-12-31 | −£154,000 | — | — |
Crism Therapeutics ebitda trends
Between the periods ended 2023-12-31 and 2025-12-31, Crism Therapeutics's ebitda decreased from −£154,000 to −£1.9M, a change of −£1.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Crism Therapeutics source filings ↗Community posts
CRISM reports higher development spending and a £1.41 million loss
CRISM Therapeutics ($CRTX) reported a first-half loss of £1.413 million, compared with £0.930 million a year earlier. Administrative expenses reached £1.52 million, including £956,000 of research and development spending. Operating cash out ...
